NDAORALSOLUTION
Approved
Jun 2011
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REZIRA is an oral solution combining hydrocodone bitartrate (opioid analgesic) and pseudoephedrine hydrochloride (decongestant) approved in 2011 for cough and nasal congestion relief. This fixed-dose combination addresses both upper respiratory symptoms and cough suppression in a single formulation. The hydrocodone provides central cough suppression while pseudoephedrine reduces nasal congestion through sympathomimetic action.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30), suggesting established market position but potential for team optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
REZIRA positions careers in commercial execution and market maintenance roles rather than innovation; professionals on this product manage an established brand in a competitive segment with opioid-related regulatory complexity. Career growth depends on defending market share, managing reimbursement pressure, and navigating DEA scheduling constraints rather than clinical advancement.
Brand Manager
Worked on REZIRA at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.